What is HC Wainwright’s Forecast for PSTV FY2028 Earnings?

Plus Therapeutics, Inc. (NASDAQ:PSTV) – Equities researchers at HC Wainwright issued their FY2028 earnings per share (EPS) estimates for Plus Therapeutics in a research report issued to clients and investors on Friday, November 15th. HC Wainwright analyst S. Lee forecasts that the company will post earnings per share of $0.28 for the year. HC Wainwright currently has a “Buy” rating and a $8.00 target price on the stock. The consensus estimate for Plus Therapeutics’ current full-year earnings is ($2.00) per share.

Separately, Ascendiant Capital Markets decreased their target price on Plus Therapeutics from $21.00 to $20.00 and set a “buy” rating for the company in a research report on Tuesday, September 3rd.

Plus Therapeutics Stock Down 7.1 %

Shares of Plus Therapeutics stock opened at $1.17 on Monday. The stock has a market cap of $6.90 million, a PE ratio of -0.46 and a beta of 0.69. The business has a fifty day simple moving average of $1.40 and a 200-day simple moving average of $1.67. Plus Therapeutics has a 12 month low of $1.15 and a 12 month high of $2.78.

Institutional Trading of Plus Therapeutics

An institutional investor recently bought a new position in Plus Therapeutics stock. AIGH Capital Management LLC acquired a new stake in shares of Plus Therapeutics, Inc. (NASDAQ:PSTV) in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 568,681 shares of the company’s stock, valued at approximately $836,000. AIGH Capital Management LLC owned about 9.98% of Plus Therapeutics at the end of the most recent quarter. 3.28% of the stock is owned by hedge funds and other institutional investors.

Plus Therapeutics Company Profile

Plus Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead radiotherapeutic drug candidate is rhenium (186Re) obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers.